Summary
Dr. Antonio D'Alessio is a Medical Oncologist and a clinical scientist with a special interest in liver cancer and immunotherapy.
He graduated with honors at the University Federico II of Naples in Italy, and then he moved to Milan where he completed his Specialty Training in Medical Oncology at Humanitas University, being currently registered to the GMC as Specialist in Medical Oncology. During his training period, he attended some of the most important European cancer institutes, namely Institut Bordet in Bruxelles, Belgium, and Hospital Clínico Universitario de Valencia in Spain. From May 2021, he started to work as Honorary Research Fellow at Imperial College London and at Hammersmith Hospital, within the early phase clinical trial unit. He is currently working on a translational PhD project focused on biomarker discovery in early-stage liver cancer treated with immune checkpoint inhibitors.
Over the last years, he has practised oncology at IRCCS Humanitas Research Hospital, one of the most renowned cancer centres in Italy. He has been directly involved in managing and treating patients with solid tumors in all phases of the disease. In particular, he grew a special interest in hepatobiliary cancers, and he has been actively involved as sub-investigator in many clinical trials of national and international relevance.
Antonio has been able to attract independent funding for his research, including the highly competitive CRUK Predoctoral Bursary. He was also awarded the "Andrew K. Burroughs Training Fellowship" from the European Association for the Study of the Liver (EASL), an internationally relevant award given to two applicants every year. The title of the project is "Integrated characterisation of anti-tumour immunity following neoadjuvant immunotherapy of hepatocellular carcinoma", that Antonio is developing during his fellowship at Imperial College.
His work has been meet with international resonance, with a number of presentations at major Oncology meetings, including ASCO, EASL, ILCA. He was awarded the prestigious ASCO Merit Awards for two consecutive years (2022 and 2023) and the ILCA Young Investigator Award for his translational work in the field of neoadjuvant immunotherpay for liver cancer.
He is an active member of the main hepatology and oncology scientific societies (ESMO, ASCO, AACR, EASL, ILCA, AIOM). His scientific activity has resulted in several works presented at national and international congresses and in a number of peer-reviewed publications and book chapters.
Publications
Journals
Pinato DJ, D'Alessio A, Fulgenzi CAM, et al., 2024, Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study., Clin Cancer Res
Pinato DJ, Fulgenzi CAM, D'Alessio A, 2024, Immunotherapy at all stages of hepatocellular carcinoma., Nat Med, Vol:30, Pages:640-641
Balcar L, Scheiner B, Fulgenzi CAM, et al., 2024, A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma., Jhep Rep, Vol:6
D'Alessio A, Rimassa L, 2024, The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma., Med, Vol:5, Pages:7-9
Agirrezabal I, Bouattour M, Pinato DJ, et al., 2024, Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison., Eur J Cancer, Vol:196